NCT02916394 is a NA clinical trial of 68Ga-NODAGA-ZIGF-1R:4：40 in Molecular Imaging, sponsored by Harbin Medical University.

Who is sponsoring NCT02916394?

NCT02916394 is sponsored by Harbin Medical University.

What drugs are being tested in NCT02916394?

Interventions in NCT02916394: 68Ga-NODAGA-ZIGF-1R:4：40.

What condition does NCT02916394 study?

NCT02916394 studies Molecular Imaging.

Is NCT02916394 still recruiting?

NCT02916394 is currently status unknown. Last updated 21 February 2020.

Last reviewed 2020-02-21 · How we verify

NCT02916394

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule

Status unknown NA Last updated 21 February 2020

What this trial tests

NA trial testing 68Ga-NODAGA-ZIGF-1R:4：40 in Molecular Imaging in 100 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Harbin Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	100
Start date	1 September 2018
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

68Ga-NODAGA-ZIGF-1R:4：40

Conditions studied

Molecular Imaging — all drugs for Molecular Imaging →

Sponsor

Harbin Medical University

Who can join

Adults 18 to 80, any sex, with Molecular Imaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators developed \[68Ga\]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.
Luo R, Liu H, Cheng Z. · · 2022 · cited 37× · PMID 35866165 · DOI 10.1039/d2cb00094f
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, et al · · 2018 · cited 8× · PMID 30139840 · DOI 10.1634/theoncologist.2018-0315

Verify or expand the search:

Other recruiting trials for Molecular Imaging

Currently open trials in the same condition.

NCT06830382 — HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · recruiting
NCT07294638 — Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Can · recruiting
NCT07531329 — Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Pro · recruiting

Other Harbin Medical University trials

Trials by the same sponsor.

NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02916394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
Last refreshed: 21 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02916394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing